Abbvie Inc. vs Vertex Pharmaceuticals Inc
ABBV vs VRTX — side-by-side comparison from reported financials. ABBV leads 3, VRTX leads 5 of 8 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Vertex Pharmaceuticals Inc
VRTX · Healthcare
$510.00+1.34%Mixed
| Metric | ABBV | VRTX |
|---|---|---|
| Price | $276.43 | $510.00 |
| Market cap | $488B | $129B |
| Revenue (TTM) | $64.4B | $12.6B |
| Revenue growth | +1.8% | +10.3% |
| Net margin | 9.8% | 35.0% |
| Free cash flow | $18.2B | $3.80B |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | +22.9% |
| P/E | 77.4 | 29.3 |
| P/E vs own history (cheap-side %) | 23% | 29% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 23% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 57,000 | 6,400 |
Full résumé-style profiles: ABBV CV · VRTX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.